Hims & Hers: U.S. Revenue Reacceleration Is Reassuring, And Valuation Compression Is Compelling (Upgrade)

Hims & Hers was upgraded to buy as revenue growth reaccelerated and its valuation compressed. Q2 revenue rose 38% year over year, including 31% organic growth, while subscribers approached 3 million despite margin pressure. The company targets more than $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, implying over 20% revenue CAGR and roughly 44% EBITDA CAGR from 2026-2030.

Analysis

The investable question is whether HIMS can convert subscriber growth into durable cohort economics before customer-acquisition costs and fulfillment complexity absorb the operating leverage. The 2030 framework requires sustained expansion in higher-frequency chronic-care categories, not merely continued acquisition in commoditized telehealth; retention, revenue per subscriber, and contribution margin by specialty are therefore more decision-useful than headline subscriber additions. A credible improvement in these KPIs could justify multiple expansion versus digitally native healthcare peers, while another quarter of gross-margin pressure would expose the long-dated EBITDA target as promotional rather than structural.

Competitive intensity is likely to rise where HIMS is seeing the best demand, particularly from Ro, Amazon Pharmacy/One Medical, GoodRx and incumbent pharmacy benefit channels. The underappreciated risk is that drug-price normalization or tighter compounding enforcement can lower nominal revenue while increasing churn if HIMS cannot preserve affordability through branded or pharmacy-partnership alternatives. Conversely, a transition toward personalized care, laboratory testing and recurring chronic-condition protocols would make the customer relationship materially stickier and reduce reliance on paid social acquisition.

Near term, the upgrade is unlikely to be sufficient on its own after a strong fundamentals narrative; the next 1-3 month catalyst is evidence that margin pressure has stabilized without a deceleration in organic growth. Over 6-18 months, the thesis depends on EBITDA conversion: HIMS must demonstrate that incremental revenue generates meaningfully higher operating profit despite regulatory, pharmacy and marketing costs. Falsify a constructive view if organic growth falls below the low-20% range for two quarters, adjusted EBITDA margins fail to expand year-over-year, or regulatory changes impair key treatment-category economics.

Key Decisions for Investors

• Initiate a starter long HIMS only on post-earnings confirmation that organic growth remains above 25% and adjusted EBITDA margin is stable-to-up year-over-year; target a 6-12 month holding period. Scale rather than chase a sentiment-driven upgrade move, since the key rerating trigger is KPI validation, not the long-range target.
• Use a defined-risk bullish structure: buy 6-9 month HIMS call spreads, financed only if implied volatility is below the prior earnings-event range. This expresses upside from a margin/retention inflection while capping exposure to regulatory or compounding-related headline risk.
• For a relative-value expression, consider long HIMS versus short TDOC in equal dollar beta-adjusted sizing over 3-6 months. HIMS has a clearer path to consumer subscription monetization, but close the spread if HIMS reports renewed margin deterioration or TDOC demonstrates sustained membership and EBITDA stabilization.
• Set an earnings watch item for specialty-level retention, revenue per subscriber, marketing expense as a percentage of revenue, and pharmacy/fulfillment costs. Do not add to the position if management reiterates long-term EBITDA ambitions without disclosing evidence that these unit-economics variables are improving.